BioSpace News Archive

Clinical Genomics announced today that Novitas Solutions Inc. has updated its Local Coverage Determination “Biomarkers for Oncology” (L35396) to provide coverage for COLVERA ® , billed with current procedural terminology (“CPT”)

Amplo Biotechnology today announced the successful closing of an undisclosed Series Seed financing.

Compounded drugs can serve an important role for patients whose medical needs cannot be met by an FDA-approved drug.

MSU Health Care now offers remote monitoring to patients with health conditions like diabetes, hypertension, obesity, high cholesterol and heart disease through a partnership with Higi Care Everyday, powered by Assure Health.

US Medical Innovations, LLC (USMI) and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance in connection with JCRI-ABTS’s US National Stage Application.

PreciseMDX, the leading end-to-end digital health platform for laboratories that automates and simplifies the diagnostic testing experience, announces today digital shipping kits for at-home or on-site diagnostic tests designed to streamline testing for patients, labs, and clinicians.

Canon Medical announced that due to recent developments in the Covid-19 pandemic, it will be attending all further relevant, major US-based global conferences in 2021, with a digital presence only.

TISSIUM will present an e-poster on its research on a novel, atraumatic, and consistent hernia mesh fixation device at the Hernia 2021 European Hernia Society – American Hernia Society Joint Congress. The event is scheduled to be held virtually and in-person from October 13 – October 16, 2021 in Copenhagen, Denmark.

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, announced that an interim analysis from the Disrupt PAD III Observational Study showed that IVL performs consistently well across challenging peripheral vessels, lesions and patients.

Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.